Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 1,201–1,300 of 1,639
Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review
Soto-Santillán, P., Jacobo-Ruvalcaba, A., de Lay, M. W., & Orihuela-Rodríguez, Ó. (2026) · Biomedicines · doi:10.3390/biomedicines14040841
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Self-citationAcute heart failure and pulmonary hypertension
Taylor, D., & Ioannou, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00033-5
Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction
Cao, J. J. L., & Reddy, Y. N. V. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10553-8 · Cited by 1
“In patients with obesity-related HFpEF, the glucagon like-peptide 1 receptor agonist (GLP-1RA) sema-glutide caused greater weight loss coupled with improvement in 6-min walk distance, quality of life, natriuretic peptide reduction, and risk of worsening HF [74–76].”
Soloveva, A. E., Park, J. J., Apostolou, E., Böhm, M., Cannata, A. N., Fudim, M., Kittipibul, V., Mueller, S., Potapova, K., Schattenberg, J. M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag243
Afşar, B., Kanbay, M., & Afşar, R. E. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106674
He, Z., Wang, C., & Tian, H. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.035
Metabolic–inflammatory burden predicts mortality in heart failure across population and ICU cohorts
Zhang, K., & Sun, F. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200648
Kim, E. Y., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.024 · Cited by 5
Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review
Bihelek, N., Burke, S., & Barry, A. R. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag121
Adiposopathy-Based Chronic Diseases and Therapeutic Role of Semaglutide
Tiwari, A., Pahuja, V., Vipin, V. P., Erande, S. G., Indurkar, S. A., Kumar, A., Saha, I., Lahiri, K. D., Kishore, R., Alok, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_21_26
Moradi, A., Ramey, K., Tabbaa, K., Sahyouni, A., Garcez, K. S., KUMAR, S., Pan, E. H., Barton, G., Oyesanmi, O., & Subbiondo, R. J. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030063
Ipek, R., Gastl, M., & Kelm, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-96019-2_30
Sarkar, S. S., Redd, M. A., Hartman, J. J., Hwee, D. T., Bat-Erdene, A., Kim, L. H., Chuang, C., Rupert, C. E., Abi‐Gerges, N., Rodriguez, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.23.701387 · Cited by 1
贾, 秋. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.55326
Puchnerová, V., Jenšovský, M., Ošťádal, P., & Bonaventura, J. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.039
Treatment of Clusters of Risks to Prevent Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2023.12.008
The Korean Mavacamten Experience: Small Steps Toward Big Questions in HCM Care
Cho, D. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0147
Obesity and Heart Failure: The (Fried) Chicken or the Egg?
Foster, L., Byrne, K. P. A., & Rivett, G. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.08.046
SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity
van den Heuvel, R. (2025) · doi:10.55788/d9fd7622
Beyond boundaries: exploring the latest guidelines for diabetes and cardiovascular health
Ruszala, V., & Williams, R. (2025) · Practice Nursing · doi:10.12968/pnur.2025.0087
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Cheng, C., Tang, M., 张兆波, Qu, R., Pei, J., Liu, T., Qu, S., You, S., Cui, S., Wang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77260 · Cited by 1
“In HFpEF with obesity, semaglu-tide improves symptoms and reduces inflammation [ 162, 180 ], and tirzepatide reduces heart failure events [ 163 ].”
Ramadan, A., Aglan, A., Salama, B., Abdalla, M., Fath, A., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001322
Wilcox, J. E., Lund, L. H., Cox, Z. L., Ho, J. E., Lam, C. S. P., Sharma, K., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.01.024 · Cited by 3
Self-citationKalra, S., Singh, B., & Kapoor, N. (2024) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.25-04
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag043
“…in patients with obesity and established cardiovascular disease but no diabetes [10], symptomatic improvement in patients with heart failure with preserved ejection fraction and obesity [11], and slowing of kidney disease progression in patients with type 2 diabetes and chronic kidney disease [12].”
Garin, N., Carballo, D., Dash, J., Stirnemann, J., Reny, J., Vuilleumier, N., & Carballo, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341606 · Cited by 2
“As recently proposed treatments for symptomatic heart failure in obese patients lead to substantial weight loss [13–15], understanding the intertwined relations between obesity and prognosis in heart failure becomes increasingly pressing.”
Takahama, H., Nochioka, K., Miyata, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4998500
Herzinsuffizienz und Übergewicht: Semaglutid verbessert kardiovaskuläre Funktion
Krome, S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2183-4117
The GLP ‐1–Mitochondria Axis in Metabolic Aging
Chang, R., Tsai, A. P., Wang, B., & Li, C. (2026) · Aging Cell · doi:10.1111/acel.70676 · Cited by 1
“…and reduced heart-failure events in obesity-related heart failure with preserved ejection fraction, both without and with diabetes (Butler et al. 2024; Kosiborod et al. 2023; Kosiborod et al. 2024)—a phenotype closely tied to myocardial energetic impairment and reduced metabolic flexibility.”
Altés, A., Moreno, Ó., Sastre-Belío, M., Rodríguez-Urgellés, E., Pérez-Alcántara, F., Larsen, S., Martín‐Lorenzo, A., Sandín, M., & Vidal, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03644-x
“…drug with evidence of reduced risk of cardiovascular (CV) death, all‑cause mortality, stroke and myocardial infarction (MI) [48], and has shown improvement in complications such as HF with preserved ejection fraction, prediabe‑ tes, osteoarthritis and metabolic steatohepatitis [40, 47, 50, 52].”
Diversity of pleiotropic effects of semaglutide: From potential mechanisms to real clinical outcomes
Demidova, T. Y., Izmaylova, M. Y., & Shirnina, M. E. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-1-03
Midlife weight gain: challenges and solutions
Hung, S., & Adams, K. E. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001093 · Cited by 1
Ghuman, A., & Das, M. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105387 · Cited by 1
“14 The magnitude of the mortality association observed in our study exceeds that reported in randomized trials and should be interpreted cautiously, as it may reflect residual confounding or bias introduced by the exposure window.”
Treating Inflammation for Cardiovascular Prevention
Dons, M., Borchsenius, J., Abbate, A., Garshick, M. S., Biering‐Sørensen, T., & Weber, B. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01130-1 · Cited by 1
“…Heart Failure With Preserved Ejection Fraction), semaglutide 2.4 mg weekly reduced hsCRP by 43.5% in patients with obesity and HFpEF [61], and a LIRAFLAME (Effect of liraglutide om vascular inflammation in type-2 diabetes: A randomized, placebo controlled, double-blind, raise…”
InfluentialWang, H., Li, Y., Qin, C., Chen, X., Wang, K., Zhang, M., & Cheng, W. (2026) · iScience · doi:10.1016/j.isci.2026.117553 · Cited by 1
Yang, D. X., Thakur, S., Akunor, H., Stacey, R. B., & Upadhya, B. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070291 · Cited by 2
“Among patients with HFpEF and obesity (BMI ≥ 35 kg/m 2 ), treatment with semaglutide (GLP-1RA) led to greater reductions in symptoms, greater improvements in exercise function, and greater weight loss [115].”
Trenas, A., Prieto-Laín, N., Velasco, M. Á. P., Padilla-Leiva, C., Pérez-Ruiz, J. M., Ruíz-Rodríguez, F. I., Gómez‐Huelgas, R., Bernal-López, M. R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19060894 · Cited by 1
“In addition, both the STEP-HFpEF and STEP-HFpEF DM trials showed clinically meaningful improvements in symptoms, physical limitations, exercise capacity, and quality of life among patients with obesity and HFpEF, regardless of DM [11,12].”
Khan, M. D., haq, M. S. U., Shaukat, M. I., Khan, M. A., shahzad, S., shahzad, S., Jamil, M., & farooq, F. (2026) · Cardiology in the Young · doi:10.1017/s1047951126124317
Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction
Jousma, J., Han, Z., Park, J., Yan, G., Zhang, S., Kwon, Y., Nukala, S. B., Kandola, J., Pinho, S., Liew, C. W., et al. (2025) · Advanced Science · doi:10.1002/advs.202506106 · Cited by 1
Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem
Demidova, T. Y., Толмачева, К. А., & Прилепа, С. А. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-4-06
Selvadurai, M. V., Dagan, M., Mariani, J. A., Vizi, D., Dewar, E., Kaye, D. M., & Nanayakkara, S. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.07.006
Zhou, X., Jeong, S., Chen, Q., Targher, G., Byrne, C. D., Chew, N. W., Younossi, Z. M., Lip, G. Y. H., Tilg, H., George, J., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01255-z · Cited by 3
Cardiology Update December 2023: Key Takeaways from Landmark Trials
Kumar, D., & Yadav, S. (2023) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_74_23
Li, Q., Yang, T., Jin, G., & Zhou, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1930278
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Mortada, I., Lee, A. W., Buckingham, D., Quach, V., Rice, J., Mansour, S., Chatila, K., Shalaby, M., Jehle, D. V., Boyars, M. C., et al. (2026) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447261478928
“15 Subsequent analyses of the STEP-HFpEF trials demonstrated that improvements in Kansas City Cardiomyopathy Questionnaire scores were comparable between women and men despite greater weight loss among women.”
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Oldenburg, L. I. K., Haugaard, S. P., Karlsson, T., Kegel, V., Parwez, M., Wiingaard, C., & Flint, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71096
Diagnostik und Therapieansätze der Herzinsuffizienz mit erhaltener systolischer Funktion
Beyer, M., Mügge, A., Akın, İ., van Heerebeek, L., El‐Battrawy, I., & Hamdani, N. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00807-6
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177 · Cited by 1
“treatment with semaglutide 2.4 mg weekly for 52 weeks improves heart failure symptoms and exercise function among participants with obesity and heart failure with pre-served ejection fraction (HFpeF) both with [28] and without [29] concomitant type 2 diabetes.”
InfluentialFordan, S., Afridi, I., Garza, A., & Collazo-Maldonado, R. L. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686460
“Similarly, GLP1-RAs were also initially used to treat T2D, and now some incretin drugs are also indicated for cardiovascular protection, diabetic nephropathy, weight loss, and sleep apnea, and have supportive data for HF [48–50].”
Hierarchical endpoints and win statistics for geromedicine trials
Abdellatif, M., Kim, Y., & Kroemer, G. (2026) · Nature Aging · doi:10.1038/s43587-026-01158-3
The adipose organ–capacitor model of preclinical and clinical obesity
Nisoli, E. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.013
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Advances in Diagnosis and Treatment of Heart Failure with Ejection Fraction Preservation
徐, 冉. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541278
Kamal, M. (2026) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2026.101977
Long-Term Impact of Clinical Obesity on Heart Failure Development and Prognosis
liu, H., Liu, T., Wu, Y. T., Zhao, H., Lin, L., Gao, X., & Wu, S. L. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.031 · Cited by 3
Yu, F.-C., Wu, C., Sung, S., Wu, Y., Hsiao, C., Chang, K.-C., Tzeng, B., Tsai, C., & Hung, C. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.032
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Chaparala, P., Rongali, D. A., Khot, M., Rangachari, B., Ahmed, K. U., Suri, S., Greeshma, M., & Shafiq, M. M. (2026) · Cureus · doi:10.7759/cureus.109350
“Still, these patient populations cannot be applied generally to all patients with obesity [20-22].”
InfluentialProsecký, R., & Karoliová, K. H. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.041
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
GLP-1-receptoragonisten en renoprotectie in type 2-diabetes
Muskiet, M. H. A., & Apperloo, E. M. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1567-6
Nuevo algoritmo de redGDPS 2026: de la glucemia al paciente
Soidán, F. J. G., Menéndez, S. A., Lachica, L. Á., Pato, Ó. B., Pradas, N. C., Teixidó, C. H., Vela, N. S., Mera-Gallego, I., & Carretero-Anibarro, E. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.4.art2 · Cited by 1
Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10671-x
“…by an increased risk of all-cause mortality and HF hospitalizations and contributes to HFpEF through multiple interconnected pathways, including systemic inflammation, neurohormonal activation, and metabolic dysregulation, all of which impair cardiovascular structure and function [10, 11].”
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Heinen, A., Spychala, A., Ballmann, L., Gödecke, S., Faradj, Z., Bottermann, K., Zabri, H., Fischer, J. W., Petzsch, P., & Gödecke, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.23.684124
“…as obesity and diabetes in the development of HFpEF is supported by clinical trials showing that antidiabetic sodium-23 glucose cotransporter 2 inhibitors (SGLT2i) as well as obesity-reducing glucagon-like peptide-1 receptor agonists (GLP-1RA) have favorable effects in HFpEF patients (11, 12).”
Hacking, D. F., Baqar, S., Vaughan, R., & Craven, A. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355289
“19 However, it was soon noted that their efficacy extended well beyond weight loss into the treatment of HFpEF 20–22 and MASH.”
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Ferreira, V. M., & Muller, V. A. (2026) · Cureus · doi:10.7759/cureus.110621
Shi, F., Agrawal, V., Munkhjargal, U., Kobeck, E., Patel, H. U., Zhang, W., & Collins, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.02.640935
“Drugs originally developed for diabetes and obesity, such as sodium-glucose transport protein 2 inhibitors and incretin-based weight loss medications, have shown clinically significant benefits in HFpEF 30-32 , suggesting targeting such comorbidities is a valid therapy for HFpEF.”
Lungeanu, L., Tache, M., Radu, A. C., Dobjanschi, C. G., Adamescu, P., Nica, A., Rusu, E., & Radulian, G. (2024) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2024.1.2
Khidhir, A., & Kalra, D. K. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01451-x
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
Singla, A., Kaur, G., Singh, G., Luthra, S., Lodha, C., Alneser, O., Alo, M. S., Ali, S. K. S., & Zulqarnain, M. A. (2026) · Cureus · doi:10.7759/cureus.113371
“Semaglutide's post-marketing use encompasses patients with heart failure with preserved ejection fraction (HFpEF), where the SELECT trial population included many such individuals, and the STEP-HFpEF trial demonstrated symptom and exercise capacity benefits of semaglutide in this subgroup [19].”
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Goubar, T., Goubar, C., Fenton‐Lee, D., Stefanidis, A., Macdonald, P. S., & Rushworth, R. L. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.018
When Better is Worse: A Paradox of the Win Ratio and Net Treatment Benefit
Fu, V. (2026) · Statistics in Medicine · doi:10.1002/sim.70580
“The win ratio has been used in a range of cardiovascular applications; for example, recent heart failure trials of semaglutide reported hierarchical composite endpoints analyzed using a win-ratio approach [3, 4].”
Sex and Gender Differences in Cardiovascular Disease
Mehta, P. K., Mathews, L. M., Chandrashekar, P., Prasad, M., Miller, V. M., Sharma, K., Sedlak, T., Merz, C. N. B., Ouyang, P., & Vaccarino, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00085-6
Self-citationSiddiqi, T. J., Khan, M. M., Fonarow, G. C., Butler, J., & Greene, S. J. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf004
Self-citationBeyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“For HFpEF, the STEP-HFpEF program (72 – 74) and SUMMIT (75) established symptom, functional, and clinical-event improvement with weight loss and circulatory volume reduction; the SUMMIT secondary analysis (3) demonstrated reductions in systolic blood pressure, estimated blood volume, C-reactive…”
InfluentialVashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.13.25333579 · Cited by 2
(2025) · doi:10.21203/rs.3.rs-6449183/v1 · Cited by 100
Parsing the Adipokine Axis in HFpEF
Verma, S., & Bhatt, D. L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.035 · Cited by 2
Self-citationRodríguez, J. M. F., Ortiz, M. B. A., Casado, J., Chivite, D., Romano, P. C., Alonso, R. G., Almorós, A. L., Miramontes‐González, J. P., Rangel, L. S., & Pérez-Silvestre, J. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502471
Black, N., Soltani, F., Bradley, J., Williams, S. G., Reid, A. B., Nucifora, G., Schmitt, M., Petrie, M. C., & Miller, C. (2026) · Cureus · doi:10.7759/cureus.108732
“Such modelling needs to be revisited now that several effective treatments for HFpEF are available, including sodium-glucose cotransporter 2 inhibitors [25,26], glucagon-like 1 peptide receptor agonists [27,28], and mineralocorticoid receptor antagonists [29].”
Self-citationClinical Implications of Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction
Ibe, T., Naser, J. A., Harada, T., Tada, A., DOI, S., Reddy, Y. N. V., Melenovský, V., Jensen, M. D., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.07.014
Self-citationTakahama, H., Nochioka, K., Miyata, S., Hayashi, H., Inoue, T., Susukita, K., Oyama, K., Shiroto, T., Takahashi, J. A., Shimokawa, H., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134062 · Cited by 1
Semaglutide reduces proteomic organ-specific biological age across randomized clinical trialsPreprint
Dermit, M., Colhoun, H. M., Goeminne, L. J. E., Ryan, D. H., Adelborg, K., Belmont-Rausch, D. M., Kolnes, K. J., Knop, F. K., Voisin, S. A. C., Gladyshev, V. N., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11082091/v1
ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
Iacovoni, A., Navazio, A., Luca, L. D., Gori, M., Corda, M., Milli, M., Iacoviello, M., Lenarda, A. D., Tano, G. D., Marini, M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf070
“The 113 used different diagnostic criteria from the guidelines ( Table 4 ).”
Self-citationDo Heart Failure With Preserved Ejection Fraction Treatments Work by Targeting Adipose Biology?
Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.046 · Cited by 1
Self-citationHighlighting the latest research: February 2024
Palmer, S. J., & Cowan, H. (2024) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2023.0104
Urbanowicz, T. K., & Filipiak, K. J. (2026) · Cells · doi:10.3390/cells15141308 · Cited by 1
Jagasia, K., Pfeiffer, A. M., & Vitale, K. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100083 · Cited by 2
“Randomized trials with comparator groups (Kosiborod et al., 2023; Pandey et al., 2024; Sattar et al., 2025) can support cautious statements about treatment effects on muscle quality and functional endpoints [47, 48,50].”
InfluentialHow Somatic Mutations cause Aging without Causing AgingPreprint
Wolf, A. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6431458
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Ceramide as a Biomarker for HFpEF in Women: Menopause, Aging, and Pregnancy
Magaye, R., Kaye, D. M., & Wang, B. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110800 · Cited by 1
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Metabolic syndrome and heart failure
Lopatin, Y. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6540 · Cited by 1
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.